ADC Therapeutics SA - ADCT STOCK NEWS

ADC Therapeutics (NYSE: ADCT) announced a conference call scheduled for February 28, 2023, at 8:30 a.m. ET to discuss its Q4 and year-end 2022 financial results and recent business updates. The call can be accessed via a registration link provided in the release, with a live webcast available on the company's investor relations website. ADC Therapeutics, based in Lausanne, Switzerland, focuses on improving cancer treatment through its proprietary antibody drug conjugates. The FDA has approved their product, ZYNLONTA, for certain types of lymphomas, and the company is advancing multiple ADCs in clinical development.

ADC Therapeutics SA (NYSE: ADCT) has announced the pricing of an underwritten offering of 12,000,000 common shares owned by A.T. Holdings II Sàrl at $5.00 per share. The sale is set to close on February 6, 2023, and ADCT will not receive any proceeds from this transaction, as it is solely from the Selling Shareholder. Notable institutional investors participating in the offering include Redmile Group, Perceptive Advisors, and Frazier Life Sciences. The offering follows a previously filed effective registration statement with the SEC. ADC Therapeutics focuses on next-generation antibody drug conjugates to treat cancer.

ADC Therapeutics SA (NYSE: ADCT) announced that CEO Ameet Mallik will participate in two investor conferences in February. The first event is the Guggenheim Healthcare Talks – Oncology Day, scheduled for February 8, from 3:55 p.m. to 4:20 p.m. ET. The second is the SVB Securities Global Biopharma Conference, taking place virtually on February 14, from 8:00 a.m. to 8:30 a.m. ET. Webcasts for both events will be accessible on ADC Therapeutics’ investor website. ADC Therapeutics specializes in developing antibody drug conjugates, including ZYNLONTA, approved for treating certain types of lymphoma.

ADC Therapeutics SA (NYSE: ADCT) will present a company overview at the 41^st Annual J.P. Morgan Healthcare Conference on January 11 at 3:00 p.m. PT in San Francisco, CA. CEO Ameet Mallik will lead the discussion, which will be streamed live on the company’s website. ADC Therapeutics is focused on improving cancer treatments through its advanced antibody drug conjugates, including ZYNLONTA, FDA-approved for specific lymphoma treatment. A replay of the webcast will be available for 30 days.

ADC Therapeutics has appointed Mohamed Zaki, MD, PhD, as Chief Medical Officer, effective January 3, 2023. He will join the executive leadership team, succeeding Joseph Camardo, MD, who is stepping down. Dr. Zaki brings over 20 years of experience in oncology and hematology drug development, previously serving at AbbVie and Celgene. The CEO, Ameet Mallik, expressed confidence in Dr. Zaki's capacity to lead the development of their antibody drug conjugate pipeline, which includes the FDA-approved ZYNLONTA for treating diffuse large B-cell lymphoma.

ADC Therapeutics (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi) have received conditional marketing authorization from the European Commission for ZYNLONTA (loncastuximab tesirine) to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval, based on the LOTIS-2 trial, triggers a $50 million milestone payment to ADC Therapeutics. Sobi plans to launch ZYNLONTA in Europe, addressing a significant unmet need for DLBCL patients. The decision is valid across EU member states and may require further confirming trials.

ADC Therapeutics (NYSE: ADCT) has appointed Jose "Pepe" Carmona as Chief Financial Officer (CFO), effective December 19, 2022. He replaces Jenn Creel, who departed for other opportunities. Ameet Mallik, CEO, expressed confidence that Carmona’s extensive experience in the pharmaceutical industry will support corporate growth and enhance shareholder value. Carmona has over 20 years of leadership experience, including previous roles at Rubius Therapeutics, Radius Health, and Novartis. ADC Therapeutics focuses on developing targeted antibody drug conjugates for cancer treatment.

Freenome presented promising research at the ASH Annual Meeting regarding their multiomics platform's ability to identify biomarkers for response to ADC Therapeutics' drug, loncastuximab tesirine (lonca), in treating DLBCL. The collaboration is set to enhance the understanding of treatment efficacy and mechanisms of resistance in patients. Results indicate potential for improved patient-specific predictions using cfDNA profiling combined with clinical data. Both companies emphasize the importance of these findings in guiding treatment strategies for DLBCL patients.

Biocytogen Pharmaceuticals announced an agreement with ADC Therapeutics (NYSE: ADCT) to evaluate Biocytogen's proprietary antibodies against three tumor targets. This agreement allows ADC Therapeutics to license selected antibodies for global development, with Biocytogen retaining all rights beyond ADC development. The agreement includes an upfront payment, option-exercise fees, and milestone payments that may total tens of millions, alongside royalties on net sales. This partnership aims to leverage both companies' expertise in antibody drug conjugates (ADCs) for innovative cancer treatments.